Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935984 · ClinicalTrials.gov registry record · Phase 4
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
A Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia, sponsored by Joseph Sferra.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT03935984: Recruiting Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia, sponsored by Joseph Sferra.
NCT03935984 is a Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia that is actively recruiting participants, run by Joseph Sferra. The registered enrollment target is 37 participants, below the 747-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03935984, a Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia, is actively recruiting participants, sponsored by Joseph Sferra.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.
Primary Outcome
conversion rate from non-localizing to localizing exam
Conditions Studied
Interventions
- DRUG Calcitonin
Study Locations (1)
Ohio
- ProMedica Toledo Hospital - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT03935984 shows while recruiting
NCT03935984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 747-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Primary Hyperparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Calcitonin is the first listed.
NCT03935984 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03935984 about?
NCT03935984 is a clinical study titled "Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity". Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium w...
What is the current status of trial NCT03935984?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2019-05-29. Estimated completion is 2026-12-31.
What conditions does trial NCT03935984 study?
This clinical trial studies the following conditions: Primary Hyperparathyroidism, Hypercalcemia.
What interventions are being tested in trial NCT03935984?
The interventions under investigation include: Calcitonin (DRUG).
Who is sponsoring clinical trial NCT03935984?
This trial is sponsored by Joseph Sferra, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935984 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Parathyroid Tumor Clonal Status
RECRUITING
-
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
RECRUITING
-
Natural History Study of Parathyroid Disorders
RECRUITING
-
Glycemic Control, Type II Diabetes, Parathyroidectomy
ACTIVE NOT RECRUITING
-
Object Assessment of Improvement in Non-Specific Symptoms After Parathyroidectomy for Primary Hyperparathyroidism
COMPLETED
-
Circulating miRNA in Primary Hyperparathyroidism
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI